On August 6, 2025, the FTC filed suit to block Edwards Life Sciences from acquiring JenaValve Technologies. Edwards Life Sciences had already acquired JC Medical, the only other company developing transcatheter aortic valve replacement devices, that treat aortic regurgitation. The only other FDA approved treatment requires open heart surgery, and theses devises offer a less invasive alternative. The FTC claimed that acquiring and merging both companies would eliminate the competition that had been spurring innovation and would limit access by patients. While the claims rely on the assumption that Edwards would own both companies, the complaint alleges that Edwards has not been willing to engage in divesting from either company.

Edwards filed a response, defending that the complaint fails to state a claim, and would violate the separation of powers and due process doctrines.

Parties then jointly requested to continue administrative proceedings that would permit further discovery. On September 30, 2025, the court ordered a stay in the event that a lapse in funding shut down commission operations.